Moderna (MRNA) said late Friday it has been awarded $590 million by the US Department of Health and Human Services for the development of mRNA-based influenza vaccines.
The project will back the late-stage development and licensure of pre-pandemic mRNA-based vaccines and support the expansion of trials for up to five additional subtypes of pandemic influenza, the company said.
Moderna said that it launched a phase 1/2 trial in 2023 to get safety and immunogenicity data of a candidate pandemic influenza vaccine, mRNA-1018, in adults. The trial included vaccine candidates against the H5 and H7 bird flu viruses.
Based on positive preliminary results from the phase 1/2 trial, the company said it is preparing to move mRNA-1018 into phase 3.
Moderna shares were rising 3.7% in after-hours activity.
Price: 35.31, Change: +1.25, Percent Change: +3.67
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。